Literature DB >> 31860552

CORR Insights®: Thirty-day Postoperative Complications After Surgery for Metastatic Long Bone Disease Are Associated With Higher Mortality at 1 Year.

Adam S Levin1.   

Abstract

Entities:  

Mesh：

Year:  2020        PMID： 31860552      PMCID： PMC7438156          DOI： 10.1097/CORR.0000000000001096

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN： 0009-921X            Impact factor:   4.755


× No keyword cloud information.
  13 in total

1.  Predictors of survival after intramedullary nail fixation of completed or impending pathologic femur fractures from metastatic disease.

Authors:  Ronak N Kotian; Varun Puvanesarajah; Sandesh Rao; Jad M El Abiad; Carol D Morris; Adam S Levin
Journal:  Surg Oncol       Date:  2018-05-31       Impact factor: 3.279

2.  Prophylactic Versus Postfracture Stabilization for Metastatic Lesions of the Long Bones: A Comparison of 30-day Postoperative Outcomes.

Authors:  Jad M El Abiad; Micheal Raad; Varun Puvanesarajah; Sandesh S Rao; Carol D Morris; Adam S Levin
Journal:  J Am Acad Orthop Surg       Date:  2019-08-01       Impact factor: 3.020

3.  Survival in patients operated on for pathologic fracture: implications for end-of-life orthopedic care.

Authors:  Saminathan S Nathan; John H Healey; Danilo Mellano; Bang Hoang; Isobel Lewis; Carol D Morris; Edward A Athanasian; Patrick J Boland
Journal:  J Clin Oncol       Date:  2005-09-01       Impact factor: 44.544

4.  Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study.

Authors:  Karim Fizazi; Michael Carducci; Matthew Smith; Ronaldo Damião; Janet Brown; Lawrence Karsh; Piotr Milecki; Neal Shore; Michael Rader; Huei Wang; Qi Jiang; Sylvia Tadros; Roger Dansey; Carsten Goessl
Journal:  Lancet       Date:  2011-02-25       Impact factor: 79.321

5.  Can We Estimate Short- and Intermediate-term Survival in Patients Undergoing Surgery for Metastatic Bone Disease?

Authors:  Jonathan A Forsberg; Rikard Wedin; Patrick J Boland; John H Healey
Journal:  Clin Orthop Relat Res       Date:  2016-12-01       Impact factor: 4.176

6.  CT-based Structural Rigidity Analysis Is More Accurate Than Mirels Scoring for Fracture Prediction in Metastatic Femoral Lesions.

Authors:  Timothy A Damron; Ara Nazarian; Vahid Entezari; Carlos Brown; William Grant; Nathan Calderon; David Zurakowski; Richard M Terek; Megan E Anderson; Edward Y Cheng; Albert J Aboulafia; Mark C Gebhardt; Brian D Snyder
Journal:  Clin Orthop Relat Res       Date:  2016-03       Impact factor: 4.176

7.  Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study.

Authors:  Alison T Stopeck; Allan Lipton; Jean-Jacques Body; Guenther G Steger; Katia Tonkin; Richard H de Boer; Mikhail Lichinitser; Yasuhiro Fujiwara; Denise A Yardley; María Viniegra; Michelle Fan; Qi Jiang; Roger Dansey; Susie Jun; Ada Braun
Journal:  J Clin Oncol       Date:  2010-11-08       Impact factor: 44.544

8.  Can A Multivariate Model for Survival Estimation in Skeletal Metastases (PATHFx) Be Externally Validated Using Japanese Patients?

Authors:  Koichi Ogura; Tabu Gokita; Yusuke Shinoda; Hirotaka Kawano; Tatsuya Takagi; Keisuke Ae; Akira Kawai; Rikard Wedin; Jonathan A Forsberg
Journal:  Clin Orthop Relat Res       Date:  2017-05-30       Impact factor: 4.176

9.  Mortality and complications following stabilization of femoral metastatic lesions: a population-based study of regional variation and outcome.

Authors:  Bill Ristevski; Richard J Jenkinson; David J G Stephen; Joel Finkelstein; Emil H Schemitsch; Michael D McKee; Hans J Kreder
Journal:  Can J Surg       Date:  2009-08       Impact factor: 2.089

10.  Use of bone-modifying agents among breast cancer patients with bone metastasis: evidence from oncology practices in the US.

Authors:  Leah J McGrath; Robert A Overman; Diane Reams; Karynsa Cetin; Alexander Liede; Steven A Narod; M Alan Brookhart; Rohini K Hernandez
Journal:  Clin Epidemiol       Date:  2018-09-26       Impact factor: 4.790
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.